ReviewJournal of clinical medicine2020
Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- The Evolving Interplay Between Targeted Therapy and Surgery for Resectable Lung Cancer.Cancers · 2025Review
- Lung resection after initial nonoperative treatment for non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2024Article
- Salvage lung resection after immunotherapy is feasible and safe.JTCVS open · 2024Article
- Article
- Diagnosis and management of patients with stage III non‑small cell lung cancer: A joint statement by the Lebanese Society of Medical Oncology and the Lebanese Pulmonary Society (Review).Oncology letters · 2023Review
- The mPharmaceuticals (Basel, Switzerland) · 2023Article
- Endoscopic Technologies for Peripheral Pulmonary Lesions: From Diagnosis to Therapy.Life (Basel, Switzerland) · 2023Review
- [Research Progress of Treatment for NSCLC in Young Patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?World journal of surgical oncology · 2022Article
- [Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022Review
- 12 × 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Deep Q-networks with web-based survey data for simulating lung cancer intervention prediction and assessment in the elderly: a quantitative study.BMC medical informatics and decision making · 2022Article
- Efficacy and safety of thoracoscopic resection for early-stage non-small cell lung cancer.American journal of translational research · 2022Article
- Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer.Cancers · 2021Review
- Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study.Cancers · 2021Article
- The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.Translational lung cancer research · 2021Review
- Links between Inflammation and Postoperative Cancer Recurrence.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of systemic treatments with high response rates, including tyrosine kinase inhibitors and immune checkpoint inhibitors, some patients with unresectable lung cancer now have a chance to undergo radical resection after primary treatment. Although there is no general consensus regarding the definition of "unresectable" in lung cancer, the term "resectable" refers to technically resectable and indicates that resection can provide a favorable prognosis to some extent. Unresectable lung cancer is typically represented by stage III and IV disease. Stage III lung cancer is a heterogeneous disease, and in some patients with technically resectable non-small cell lung cancer (NSCLC), multimodality treatments, including induction chemoradiotherapy followed by surgery, are the treatments of choice. The representative surgical intervention for unresectable stage III/IV NSCLC is salvage surgery, which refers to surgical treatment for local residual/recurrent lesions after definitive non-surgical treatment. Surgical intervention is also used for an oligometastatic stage IV NSCLC. In this review, we highlight the role of surgical intervention in patients with unresectable NSCLC, for whom an initial complete resection is technically difficult. We further describe the history of and new findings on salvage surgery for unresectable NSCLC and surgery for oligometastatic NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.